BioCentury
ARTICLE | Clinical News

AB0024: Phase I data

September 13, 2010 7:00 AM UTC

In a dose-escalation Phase I trial in 3 patients, 1 mg/kg AB0024 every 2 weeks was well tolerated. An additional 3 patients are being enrolled at the 3 mg/kg dose level. Arresto plans to begin a Phase...